Our findings demonstrate that, in AML cells, treatment with the CDK9 inhibitor NVP-2 and the FASN inhibitor Orlistat resulted in proliferation inhibition and promotion of apoptosis. Here, CDK9 is linked to acute myeloid leukemia.